Abstract:Introduction Heart failure (HF) is understudied among women; especially, genomic evidence implicating shared or unique mechanisms of HF with respect to reduced or preserved ejection fraction (HFrEF, HFpEF) is lacking across ethnic populations of women. Prior genome-wide association studies (GWAS) have identified approximately 30 suggestive genetic variants for HF, although none have been specifically linked to HFrEF or HFpEF. Objectives We aimed to define, replicate, and annotate genetic variants to HFrEF, HFpEF, or both, as well as to investigate potential biological mechanisms underlying HFrEF and HFpEF among African American (AA) and European American (EA) women in three well-characterized, high-quality prospective cohorts, the Women’s Health Initiative (WHI) study, the Jackson Heart Study (JHS), and the Framingham Heart Study (FHS). Methods GWAS analysis on HFrEF and HFpEF were first performed among 7,982 AA and 4,133 EA in the WHI, followed by pathway analysis employing two independent methodological platforms (GSA-SNP and Mergeomics) curating KEGG, Reactome, and BioCarta pathway databases. GWAS signals and biological pathways identified using the WHI were replicated in the JHS and FHS. For all replicated pathways, we performed cross-phenotype and cross-ethnicity validation analyses to examine shared pathways between HFrEF and HFpEF, and phenotype-specific pathways, across ethnicities. We further prioritized key driver genes for HF according to specific pathways identified. Results We validated one previously reported genetic locus and identified six new ones, among which one locus was allocated to HFrEF and five to HFpEF. Additionally, we defined five biological pathways shared between HFrEF and HFpEF and discovered six HFpEF-specific pathways. These pathways overlapped in two main domains for molecular signaling: 1) inflammation and 2) vascular remodeling (including angiogenesis and vascular patterning), involving key driver genes from collagen and HLA gene families. Conclusions Our network analysis of three large prospective cohorts of women in the United States defined several novel loci for HF and its subtypes. In particular, several key driver genes reinforce the mechanistic role of inflammation and vascular remodeling in the development of HF, especially HFpEF. Given that therapeutic strategies developed for left ventricular dysfunction have had limited success for HFpEF, several new targets and pathways identified and validated in this study should be further assessed in risk stratification as well as the design of potential new HF interventions.

Sex-stratified Genome-Wide Association and Transcriptome-Wide Mendelian Randomization Studies Reveal Drug Targets of Heart Failure.

Multi-trait genome-wide analysis identified novel risk loci and candidate drugs for heart failure

A Multivariable Mendelian Randomization Study of Systolic and Diastolic Blood Pressure, Lipid Profile, and Heart Failure Subtypes

Large-scale Mendelian randomization identifies novel pathways as therapeutic targets for heart failure with reduced ejection fraction and with preserved ejection fraction

Mining Potential Drug Targets and Constructing Diagnostic Models for Heart Failure Based on Mirna-Mrna Networks

Heart Failure and Ischemic Stroke: A Bidirectional and Multivariable Mendelian Randomization Study

Biological Pathways and Gene Networks Link Inflammation and Vascular Remodeling to Both Heart Failure with Preserved and Reduced Ejection Fraction in Women across Ethnicities

Sex Differences in Cardiac and Clinical Phenotypes and Their Relation to Outcomes in Patients with Heart Failure

Sex Differences in Long-term Heart Failure Prognosis: A Comprehensive Meta-Analysis

HFpEF and sex: understanding the role of sex differences

Large-scale in Silico Identification of Drugs Exerting Sex-Specific Effects in the Heart

Navigating Heart Failure: Unveiling Sex Disparities in Guideline-Directed Medical Therapy Combinations

Smoking and heart failure: a Mendelian randomization and mediation analysis

Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure

Genome wide association study provides new insights into the genetic architecture and pathogenesis of heart failure

Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review

Sex differences and related estrogenic effects in heart failure with preserved ejection fraction

Mendelian randomization combined with multi-omics explores the relationship between heart failure and cancer

Common Variants for Heart Failure.

Discovery of Biological Pathways and Gene Networks for Heart Failure with Preserved and Reduced Ejection Fraction in Women Across Ethnicities

Sex difference in incidence and risk factors of hospitalization for heart failure, and subsequent mortality: findings from the China PEACE million persons project